PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.53% | 34.20% | 217.98% | 441.35% | -849.60% |
| Total Depreciation and Amortization | 190.29% | 731.10% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -73.53% | -333.33% | -- | -- | -- |
| Change in Net Operating Assets | 215.90% | -92.66% | -2,175.51% | 1,103.14% | -2,516.55% |
| Cash from Operations | 184.75% | -17.39% | 164.32% | 473.63% | -676.61% |
| Capital Expenditure | -- | -30,524.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -387.04% | -1,356.83% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -288.33% | -4,330.78% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.88% | -230.07% | -- | -- | -- |
| Issuance of Common Stock | -58.58% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.80% | -100.25% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.33% | -116.89% | 125.78% | -4,522.81% | 5,979.90% |